Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.31 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.31 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7190576 | 1.00 | TSHR (0.52) | TSHRALDH1A1SMN1; SMN2HPGDGRIK1 | |
| SCHEMBL41974 | 1.00 | TSHR (0.52) | TSHRALDH1A1SMN1; SMN2HPGDGRIK1 | |
| SCHEMBL10587204 | 0.82 | TSHR (0.57) | TSHRALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL10587210 | 0.82 | TSHR (0.57) | TSHRALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL15673048 | 0.80 | TSHR (0.50) | TSHRALDH1A1SMN1; SMN2HPGDGPR35 | |
| SCHEMBL28467655 | 0.79 | NPSR1 (0.43) | TSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL7586059 | 0.79 | NPSR1 (0.43) | TSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL7586064 | 0.79 | NPSR1 (0.43) | TSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL11800167 | 0.78 | TSHR (0.53) | TSHRALDH1A1SMN1; SMN2HPGDGPR35 | |
| SCHEMBL7284423 | 0.76 | TSHR (0.46) | TSHRALDH1A1SMN1; SMN2HPGDGRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 302 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130131032-A1 | NEUROTHERAPEUTIC TREATMENT FOR SEXUAL DYSFUNCTION | REVAAX PHARMACEUTICALS, LLC (US) | 2013-05-23 | — | — | US | claimed |
| US-7355040-B2 | Process for the preparation of cephalosporin compounds and synthetic intermediates | ZOETIS SERVICES LLC | 2008-04-08 | — | — | US | claimed |
| EP-0849269-B9 | Vinyl pyrrolidine cephalosporins with basic substituents | BASILEA PHARMACEUTICA AG (CH) | 2003-03-05 | — | — | EP | claimed |
| EP-0849269-B1 | Vinyl pyrrolidine cephalosporins with basic substituents | BASILEA PHARMACEUTICA AG (CH) | 2002-07-10 | — | — | EP | claimed |
| US-5763603-A | HIGH BETA-LACTAMASE INHIBITORY ACTIVITY IN COMBINATION WITH BETA-LACTAM ANTIBIOTICS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 1998-06-09 | — | — | US | claimed |
| US-5712268-A | Compositions of tricyclic β-lactams and uses thereof | HOFFMANN-LA ROCHE INC. (US) | 1998-01-27 | — | — | US | claimed |
| US-5698577-A | ANTIBIOTICS | HOFFMANN-LA ROCHE INC. (US) | 1997-12-16 | — | — | US | claimed |
| EP-0508234-B1 | Beta-lactames | HOFFMANN LA ROCHE (CH) | 1996-07-24 | — | — | EP | claimed |
| US-5494666-A | BETA-LACTAMASE INHIBITORS, ANTIBACTERIALS | HOFFMANN-LA ROCHE INC. (US) | 1996-02-27 | — | — | US | claimed |
| US-5464617-A | 1H-2,6a-diazacyclobut(cd)indene-6-carboxylic acid derivatives, antibiotics | HOFFMANN-LA ROCHE INC. (US) | 1995-11-07 | — | — | US | claimed |
| EP-0671401-A1 | Beta lactames | F. HOFFMANN-LA ROCHE AG (CH) | 1995-09-13 | — | — | EP | claimed |
| EP-0508234-A2 | Beta-lactames | F. HOFFMANN-LA ROCHE AG (CH) | 1992-10-14 | — | — | EP | claimed |
| US-10010616-B2 | Immunogenic compositions and reagents for preparing | PURDUE RESEARCH FOUNDATION (US) | 2018-07-03 | — | — | US | disclosed |
| US-9782491-B2 | Peptide conjugates for treating pain | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2017-10-10 | — | — | US | disclosed |
| US-9505747-B2 | Processes for preparing tubulysin derivatives and conjugates thereof | ENDOCYTE, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-9480679-B2 | Methods for treating malaria, tuberculosis and MAC diseases | CEMPRA PHARMACEUTICALS, INC. (US) | 2016-11-01 | — | — | US | disclosed |
| WO-1992001695-A1 | CEPHALOSPORINS AND HOMOLOGUES, PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS | BEECHAM GROUP PLC (GB) | 1992-02-06 | — | — | WO | disclosed |
| WO-1992001696-A1 | CEPHALOSPORINS AND HOMOLOGUES, PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS | BEECHAM GROUP PLC (GB) | 1992-02-06 | — | — | WO | disclosed |
| EP-0395219-A2 | Cephalosporins and their homologues, process for their preparation and pharmaceutical compositions | Beecham Group p.l.c. (GB) | 1990-10-31 | — | — | EP | disclosed |
| EP-0318767-A2 | Esters of pharmacologically active carboxylic acids splittable under physiological conditions | F. HOFFMANN-LA ROCHE AG (CH) | 1989-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131032-A1 | NEUROTHERAPEUTIC TREATMENT FOR SEXUAL DYSFUNCTION | PREP, DNPEP, PRSS12 | TSHR 3894/4885ALDH1A1 1573/4885SMN1; SMN2 518/4885 |
| US-10010616-B2 | Immunogenic compositions and reagents for preparing | FCGRT, HLA-DRB1, CD47 | TSHR 3774/4885ALDH1A1 4566/4885SMN1; SMN2 2380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.